TL;DR
Get comfort and care essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA approved AbbVie’s once-daily Parkinson’s pill Juvmo (tavapadon) on Sept. 25 as a standalone treatment for early Parkinson’s and as an add-on in later stages. In three Phase 3 trials with over 1,300 participants, it improved motor symptoms and extended ‘on time’ with milder side effects than many existing drugs.
The U.S. Food and Drug Administration has approved AbbVie’s once-daily Parkinson’s pill Juvmo, known as tavapadon during clinical trials, as a treatment for Parkinson’s motor symptoms, according to a report by Being Patient. The approval, granted on Sept. 25, allows the drug to be used as a standalone treatment in early-stage Parkinson’s or as an add-on to existing medications in later stages. The decision matters because more than one million people in the U.S. live with Parkinson’s, and many current medications must be taken multiple times a day and carry side effects that lead some patients to stop treatment within the first year.
Juvmo was tested in three 26-week Phase 3 placebo-controlled randomized trials involving more than 1,300 participants. The first two trials, which tested the drug as a standalone medication, found it produced noticeable and meaningful improvements in motor symptoms — including tremors, rigidity, slow movements, and posture problems — with mild to moderate side effects such as nausea and headache, according to Being Patient’s report.
The third trial tested Juvmo as an add-on therapy and found it helped prolong “on time,” the period when a Parkinson’s medication is working, and reduce “off time,” when its effects wear off. AbbVie said it expects the drug to be available in October 2026.
The drug works differently from existing treatments. In Parkinson’s, neurons that produce the neurotransmitter dopamine die off, producing the disease’s motor symptoms. Current medications called dopamine agonists mimic dopamine by activating the D2 and D3 receptor proteins, a pathway linked to many side effects. Juvmo instead activates the D1 and D5 receptors, targeting other dopamine pathways — a mechanism that, according to the report, results in fewer unwanted effects such as dyskinesia, the erratic and uncontrolled movements associated with existing therapies.
Why a Once-Daily Option Matters
The approval addresses two persistent problems in Parkinson’s care: dosing burden and side effects. Many existing medications must be taken multiple times a day, and side effects including dyskinesia and impulse control disorder — which can cause problematic behaviors such as gambling — lead some patients to discontinue their medications within the first year, according to Being Patient.
Dr. Hubert Fernandez, professor and neurologist at the Cleveland Clinic and global investigator on two of the drug’s Phase 3 trials, said the approval “provides health care providers with greater flexibility to tailor treatment to individual patient needs.” He noted that Parkinson’s treatment “has long required health care providers to balance the need for dependable motor symptom control with considerations around treatment tolerability.”
Clinicians have offered a measured assessment of the drug’s place in care. Dr. Bryan Ho, neurologist and director of the Movement Disorders Program at Tufts Medical Center, told Being Patient: “It’s not a huge game-changer, but definitely a nice additional tool to have.” He said he sees it as especially useful for older patients, who are more vulnerable to the side effects of other therapies.
How Juvmo Differs From Existing Drugs
Parkinson’s disease involves the progressive death of dopamine-producing neurons, which drives the motor symptoms that define the condition. Standard treatments manage these symptoms rather than slow the underlying disease, and dopamine agonists — which activate D2 and D3 receptors — have been a mainstay, though activating that circuitry is linked to side effects such as dyskinesia and impulse control problems.
Juvmo’s D1/D5 receptor mechanism represents an alternative route to stimulating dopamine pathways. Its dual approval pathway — standalone for early disease and add-on for later stages — mirrors how Parkinson’s treatment typically unfolds: patients often begin with a single medication and add or switch drugs as symptoms progress and medication effects shorten over time. The FDA’s approval covers symptom treatment only; it is not a disease-modifying therapy.
“It’s not a huge game-changer, but definitely a nice additional tool to have.”
— Dr. Bryan Ho, neurologist and director of the Movement Disorders Program at Tufts Medical Center, previously told Being Patient
What the Trials Could Not Yet Show
The 26-week duration of the Phase 3 trials means they are not long enough to determine whether the treatment reduces the risk of impulse control problems, according to the report. Longer-term safety and tolerability data beyond six months is not yet established.
It is also not yet clear how the drug’s pricing, insurance coverage, or real-world tolerability will shape its use once it reaches pharmacies. The report does not state the cost of the medication. And while the trials showed symptom improvement, Juvmo has not been shown to slow or alter the underlying progression of Parkinson’s disease.
Launch Timeline and Patient Access
AbbVie expects Juvmo to be available in the U.S. in October 2026, according to the report. Patients and caregivers can discuss with their neurologists or movement-disorder specialists whether the drug fits their stage of disease and current treatment plan — either as a standalone option in early Parkinson’s or as an add-on in later stages. As the drug reaches the market, additional real-world data on side effects, long-term safety, and impulse control risk is expected to accumulate. Anyone considering a change in Parkinson’s treatment should consult a qualified physician.
Key Questions
When will Juvmo be available in the U.S.?
AbbVie expects the drug to be available in October 2026, according to the report.
How does Juvmo differ from existing Parkinson’s medications?
Unlike dopamine agonists, which activate the D2 and D3 receptors, Juvmo activates the D1 and D5 receptors. According to the report, this mechanism leads to fewer side effects such as dyskinesia, the erratic and uncontrolled movements linked to some existing therapies.
Can Juvmo be taken alongside other Parkinson’s treatments?
Yes. Juvmo is FDA-approved as a standalone treatment for early-stage symptoms and as an add-on treatment in later stages to prolong the effects of existing medications.
What side effects were seen in clinical trials?
In the Phase 3 trials, participants most commonly experienced mild to moderate side effects such as nausea and headache, according to the report.
Does Juvmo cure or slow Parkinson’s disease?
No. Juvmo is approved to treat motor symptoms, not to cure Parkinson’s or slow its progression. The trials measured improvements in symptoms such as tremors and rigidity and changes in “on” and “off” time.
Source: rss
Cold & flu season Picks
humidifiers
As an affiliate, we earn on qualifying purchases.
